Adolor Corporation  

(Public, NASDAQ:ADLR)   Watch this stock  
Find more results for ADLR
0.0000
- Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -0.08
Shares     -
Beta     -
Inst. own     -

Key stats and ratios

Q3 (Sep '11) 2010
Net profit margin 35.84% -62.98%
Operating margin 35.63% -66.41%
EBITD margin - -61.05%
Return on average assets 67.98% -37.82%
Return on average equity 219.74% -85.62%
Employees 75 -
CDP Score - -

Address

700 PENNSYLVANIA DRIVE
EXTON, PA 19341
United States - Map
+1-302-6587581 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Adolor Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pain and pain-management products. ENTEREG (alvimopan) is the United States Food and Drug Administration (FDA) approved product. ENTEREG is indicated to accelerate upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surgery with primary anastomosis. The Company is conducting two Phase 2 clinical trials of ADL5945 to treat opioid-induced constipation (OIC), a condition that often results from long-term use of opioid analgesics in the management of chronic pain conditions. In addition, it is continuing development efforts on ADL7445, a second peripherally-acting mu opioid receptor antagonist, which is considered a back-up compound in its OIC program. The Company has completed Phase 1 clinical evaluation of ADL6906 (beloxepin). In December 2011, Cubist Pharmaceuticals, Inc. acquired Adolor Corporation.